当前位置: 首页 >> 检索结果
1. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
作者: Rohit Aggarwal.;Priyadarshini Loganathan.;Diane Koontz.;Zengbiao Qi.;Ann M Reed.;Chester V Oddis.
来源: Rheumatology (Oxford). 2017年56卷2期247-254页
The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM.
2. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.
作者: Lesley-Anne Bissell.;Elizabeth M A Hensor.;Lukasz Kozera.;Sarah L Mackie.;Agata N Burska.;Jacqueline L Nam.;Helen Keen.;Edith Villeneuve.;Helena Donica.;Maya H Buch.;Philip G Conaghan.;Jacqueline Andrews.;Paul Emery.;Ann W Morgan.
来源: Rheumatology (Oxford). 2016年55卷12期2181-2190页
To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
3. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
作者: Pascal H P de Jong.;Johanna M Hazes.;Leander R Buisman.;Pieternella J Barendregt.;Derkjen van Zeben.;Peter A van der Lubbe.;Andreas H Gerards.;Mike H de Jager.;Peter B J de Sonnaville.;Bernard A Grillet.;Jolanda J Luime.;Angelique E A M Weel.
来源: Rheumatology (Oxford). 2016年55卷12期2138-2147页
To evaluate direct and indirect costs per quality adjusted life year (QALY) for different initial treatment strategies in very early RA.
4. Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
作者: Bruce Kirkham.;Khaldoun Chaabo.;Christopher Hall.;Toby Garrood.;Timothy Mant.;Elizabeth Allen.;Alexandra Vincent.;Joana C Vasconcelos.;Andrew T Prevost.;Gabriel S Panayi.;Valerie M Corrigall.
来源: Rheumatology (Oxford). 2016年55卷11期1993-2000页
Binding immunoglobulin protein (BiP) is a human endoplasmic reticulum-resident stress protein. In pre-clinical studies it has anti-inflammatory properties due to the induction of regulatory cells. This randomized placebo-controlled, dose ascending double blind phase I/IIA trial of BiP in patients with active RA, who had failed accepted therapies, had the primary objective of safety. Potential efficacy was measured by DAS28-ESR and changes in biomarkers.
5. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment.
作者: Glen S Hazlewood.;Claire Bombardier.;George Tomlinson.;Carter Thorne.;Vivian P Bykerk.;Andrew Thompson.;Diane Tin.;Deborah A Marshall.
来源: Rheumatology (Oxford). 2016年55卷11期1959-1968页
To quantify the preferences of patients with early RA (ERA) with the benefits and harms of DMARDs.
6. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
作者: Joachim Sieper.;Martin Rudwaleit.;Jan Lenaerts.;Jürgen Wollenhaupt.;Leysan Myasoutova.;Sung-Hwan Park.;Yeong W Song.;Ruji Yao.;Susan Huyck.;Marinella Govoni.;Denesh Chitkara.;Nathan Vastesaeger.
来源: Rheumatology (Oxford). 2016年55卷11期1946-1953页
To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission.
7. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
作者: Julie Ducreux.;Frédéric A Houssiau.;Pierre Vandepapelière.;Christian Jorgensen.;Estibaliz Lazaro.;François Spertini.;Fabien Colaone.;Camille Roucairol.;Marion Laborie.;Thérèse Croughs.;Géraldine Grouard-Vogel.;Bernard R Lauwerys.
来源: Rheumatology (Oxford). 2016年55卷10期1901-5页
IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNα Abs antibodies (Abs), and gene expression profiling.
8. A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.
作者: Morten Aagaard Nielsen.;Thomas Andersen.;Anders Etzerodt.;Tue Wenzel Kragstrup.;Tue Kruse Rasmussen.;Kristian Stengaard-Pedersen.;Merete Lund Hetland.;Kim Hørslev-Petersen.;Peter Junker.;Mikkel Østergaard.;Malene Hvid.;Søren K Moestrup.;Bent Deleuran.
来源: Rheumatology (Oxford). 2016年55卷10期1871-9页
Co-stimulatory T cell cytokines are important in the progression of RA. This study investigates the interplay between 4-1BB, a disintegrin and metalloprotease-17 (ADAM17) and galectin-9 (Gal-9) in RA.
9. Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks.
作者: Ana M Valdes.;Tina Manon-Jensen.;Abhishek Abhishek.;Wendy Jenkins.;Anne Sofie Siebuhr.;Morten A Karsdal.;Sally Doherty.;Weiya Zhang.;Helen Richardson.;Michael Doherty.;Anne-Christine Bay-Jensen.
来源: Rheumatology (Oxford). 2016年55卷9期1642-6页
Recurrent flares constitute the main clinical burden of gout. Our aim was to assess whether biomarkers measuring MMP tissue degradation could be used as markers of frequent gout flares.
10. The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.
作者: Nicole P C Konijn.;Lilian H D van Tuyl.;Maarten Boers.;Peter M van de Ven.;Debby den Uyl.;Marieke M Ter Wee.;Pit Kerstens.;Alexandre E Voskuyl.;Dirkjan van Schaardenburg.;Willem F Lems.;Michael T Nurmohamed.
来源: Rheumatology (Oxford). 2016年55卷9期1615-22页
To investigate the effect of two different high-dose, step-down prednisolone regimens on body composition in early RA patients after 26 weeks of treatment.
11. Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.
作者: Kanneboyina Nagaraju.;Svetlana Ghimbovschi.;Sree Rayavarapu.;Aditi Phadke.;Lisa G Rider.;Eric P Hoffman.;Frederick W Miller.
来源: Rheumatology (Oxford). 2016年55卷9期1673-80页
To identify muscle gene expression patterns that predict rituximab responses and assess the effects of rituximab on muscle gene expression in PM and DM.
12. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
作者: Chingching Foocharoen.;Kitti Chunlertrith.;Pisaln Mairiang.;Ajanee Mahakkanukrauh.;Siraphop Suwannaroj.;Suwassa Namvijit.;Orathai Wantha.;Ratanavadee Nanagara.
来源: Rheumatology (Oxford). 2017年56卷2期214-222页
Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc. The aim of this study was to compare the efficacy of omeprazole in combination with domperidone vs in combination with algycon in reducing the severity and frequency of reflux symptoms of PPI partial response (PPI-PR) GERD in SSc.
13. Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy.
作者: Maria I Ramos.;Marcel B M Teunissen.;Boy Helder.;Saida Aarrass.;Maria J H de Hair.;Arno W van Kuijk.;Danielle M Gerlag.;Paul P Tak.;Maria C Lebre.
来源: Rheumatology (Oxford). 2016年55卷9期1575-84页
We aimed to investigate the early changes in expression of C-type lectin domain family 9, member A (CLEC9A), a C-type lectin that is specifically expressed by the CD141(+) dendritic cell subset that is involved in cross-presentation to CD8(+) T cells, by evaluating gene and/or protein expression in three different compartments [skin, synovial tissue (ST) and serum] after short-term adalimumab treatment in PsA patients compared with placebo.
14. Erosive and osteoarthritic structural progression in early rheumatoid arthritis.
作者: Daniel F McWilliams.;Michelle Marshall.;Keeranur Jayakumar.;Sally Doherty.;Michael Doherty.;Weiya Zhang.;Patrick D W Kiely.;Adam Young.;David A Walsh.
来源: Rheumatology (Oxford). 2016年55卷8期1477-88页
To investigate factors associated with joint damage in early RA, and how comorbid OA might influence patient assessment and outcomes.
15. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
作者: Paul Emery.;Josef S Smolen.;Arijit Ganguli.;Sebastian Meerwein.;Yanjun Bao.;Hartmut Kupper.;Naijun Chen.;Arthur Kavanaugh.
来源: Rheumatology (Oxford). 2016年55卷8期1458-65页
To evaluate the effects of adalimumab plus MTX (ADA + MTX) vs MTX monotherapy on work-related outcomes in early RA patients with elevated risk of employment loss.
16. Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis.
作者: Anne A Schouffoer.;Florus J van der Giesen.;Liesbeth J J Beaart-van de Voorde.;Ron Wolterbeek.;Tom W J Huizinga.;Theodora P M Vliet Vlieland.
来源: Rheumatology (Oxford). 2016年55卷8期1386-93页
The aim was to assess the validity and responsiveness of the Michigan Hand Questionnaire (MHQ) in patients with SSc.
17. Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis.
作者: Iris M Markusse.;Robert Landewé.;Ron Wolterbeek.;Meilien Ho.;Martin Jenkins.;Désirée van der Heijde.
来源: Rheumatology (Oxford). 2016年55卷7期1295-300页
To assess linear extrapolation (LE) and last observation carried forward (LOCF) as imputation methods for radiographic change in patients with RA.
18. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis.
作者: G Esther A Habers.;G J F Joyce Bos.;Annet van Royen-Kerkhof.;Otto T H M Lelieveld.;Wineke Armbrust.;Tim Takken.;Marco van Brussel.
来源: Rheumatology (Oxford). 2016年55卷7期1251-62页
To study for the first time in a randomized controlled trial the feasibility, safety and efficacy of an exercise training programme in children and adolescents with JDM.
19. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
作者: Vibeke Strand.;Ronald F van Vollenhoven.;Eun Bong Lee.;Roy Fleischmann.;Samuel H Zwillich.;David Gruben.;Tamas Koncz.;Bethanie Wilkinson.;Gene Wallenstein.
来源: Rheumatology (Oxford). 2016年55卷6期1031-41页
To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses to MTX.
20. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
作者: Rohit Aggarwal.;Chester V Oddis.;Danielle Goudeau.;Diane Koontz.;Zengbiao Qi.;Ann M Reed.;Dana P Ascherman.;Marc C Levesque.
来源: Rheumatology (Oxford). 2016年55卷6期991-9页
To determine the longitudinal trends in serum levels of four myositis-associated autoantibodies: anti-Jo-1, -transcription intermediary factor 1 γ (TIF1-γ), -signal recognition particle (SRP) and -Mi-2, after B cell depletion with rituximab, and to determine the longitudinal association of these autoantibody levels with disease activity as measured by myositis core-set measures (CSMs).
|